Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19329080 | 1.00 | PTPN1 (0.45) | PTPN1HDAC1HDAC8NR1H2MEN1 | |
| SCHEMBL19329090 | 0.86 | PTPN1 (0.44) | PTPN1HDAC1HDAC8NR1H2MEN1 | |
| SCHEMBL19329089 | 0.86 | PTPN1 (0.44) | PTPN1HDAC1HDAC8NR1H2MEN1 | |
| SCHEMBL19460348 | 0.84 | HDAC8 (0.48) | PTPN1HDAC8NR1H2MEN1KMT2A | |
| SCHEMBL19460349 | 0.84 | HDAC8 (0.48) | PTPN1HDAC8NR1H2MEN1KMT2A | |
| SCHEMBL29798802 | 0.83 | HDAC8 (0.46) | PTPN1HDAC8NR1H2MEN1KMT2A | |
| SCHEMBL2730295 | 0.83 | HDAC8 (0.46) | PTPN1HDAC8NR1H2MEN1KMT2A | |
| SCHEMBL19329217 | 0.82 | HDAC8 (0.53) | PTPN1HDAC8 | |
| SCHEMBL19329216 | 0.82 | HDAC8 (0.53) | PTPN1HDAC8 | |
| SCHEMBL20784268 | 0.82 | PTPN1 (0.41) | PTPN1HDAC1HDAC8NR1H2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426648-B1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2021-05-12 | — | — | EP | disclosed |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2019-09-24 | — | — | US | disclosed |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2019-03-07 | — | — | US | disclosed |
| EP-3426648-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153513-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PTPN1 4467/4885HDAC1 98/4885HDAC8 707/4885 |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PTPN1 4467/4885HDAC1 98/4885HDAC8 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.